Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15675244 | 0.86 | CFD (0.49) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL15675029 | 0.84 | CFD (0.48) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL10840143 | 0.83 | ADRA2A (0.50) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL7154532 | 0.83 | ADRA2A (0.50) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL15675138 | 0.83 | CFD (0.47) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL954835 | 0.81 | CES2 (0.47) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL16070801 | 0.81 | CYP2D6 (0.52) | ADRB1ADRB2AOC3CYP2D6NFKB1 | |
| SCHEMBL22933100 | 0.81 | CFD (0.50) | CFDADRB1ADRB2AOC3CYP2D6 | |
| SCHEMBL866713 | 0.80 | ADRB2 (0.59) | ADRB1ADRB2AOC3CYP2D6NFKB1 | |
| SCHEMBL16064818 | 0.80 | ADRB2 (0.59) | ADRB1ADRB2AOC3CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4511355-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FundaMental Pharma GmbH (DE) | 2025-02-26 | — | — | EP | disclosed |
| CN-119522208-A | Effective methods for modulating NMDA receptor-mediated toxicity | 智基药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024223617-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
| US-9902742-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2739628-B1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9611274-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9221818-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | TRPM4, GRM4, GRIN1 | CFD 4489/4885ADRB1 1079/4885ADRA2A 1777/4885 |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | CFD 46/4885ADRB1 4542/4885ADRA2A 4441/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | CFD 48/4885ADRB1 4454/4885ADRA2A 4331/4885 |
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | CFD 46/4885ADRB1 4542/4885ADRA2A 4441/4885 |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | CFD 46/4885ADRB1 4542/4885ADRA2A 4441/4885 |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | CFD 46/4885ADRB1 4542/4885ADRA2A 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.